A novel approach to oral apoA-I mimetic therapy

Journal of Lipid Research

Volumn 54, Issue 4, 2013, Pages 995-1010

  Chattopadhyay, Arnab ^a   Navab, Mohamad ^a   Hough, Greg ^a   Gao, Feng ^a   Meriwether, David ^a   Grijalva, Victor ^a   Springstead, James R ^a   Palgnachari, Mayakonda N ^c   Namiri Kalantari, Ryan ^a   Su, Feng ^a   Van Lenten, Brian J ^a   Wagner, Alan C ^a   Anantharamaiah, G M ^c   Farias Eisener, Robin ^a   Reddy, Srinivasa T ^a,b   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

6F peptide; Apolipoprotein A I mimetic peptides; Atherosclerosis; Genetically engineered tomato plants; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; ASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYLASPARTYLLYSYLPHENYLALANYLPHENYLALANYLGLUTAMYLLYSYLPHENYLALANYLLYSYLGLUTAMYLPHENYLALANYLPHENYLALANINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYICOSATETRAENOIC ACID; LYCOPENE; LYSOPHOSPHATIDIC ACID; PEPTIDE; SERUM AMYLOID A; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; FATTY ACID BLOOD LEVEL; FEMALE; LIPID OXIDATION; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMALL INTESTINE; TOMATO; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN DIET;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; FEMALE; HYDROXYEICOSATETRAENOIC ACIDS; INTESTINE, SMALL; LYCOPERSICON ESCULENTUM; LYSOPHOSPHOLIPIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDES; PLANTS, GENETICALLY MODIFIED; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 84875867425     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M033555     Document Type: Article

References (36)

1. Getz, G. S., and C. A. Reardon. 2011. Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis. J. Infl amm. Res. 4 : 83-92.
2. Navab, M., S. T. Reddy, B. J. Van Lenten, G. M. Buga, G. Hough, A. C. Wagner, and A. M. Fogelman. 2012. High-density lipoprotein and 4F peptide reduce systemic infl ammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler. Thromb. Vasc. Biol. 32 : 2553-2560.
3. Degoma, E. M., and D. J. Rader. 2011. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 8 : 266-277.
4. Yao, X., M. P. Vitek, A. T. Remaley, and S. J. Levine. 2012. Apolipoprotein mimetic peptides: a new approach for the treatment of asthma. Front. Pharmacol. 3 : 37.
5. Navab, M., I. Shechter, G. M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman. 2010. Structure and function of HDL mimetics. Arterioscler. Thromb. Vasc. Biol. 30 : 164-168.
6. Bloedon, L. T., R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B. J. DeGroot, R. Movva, M. Navab, A. M. Fogelman, and D. J. Rader. 2008. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49 : 1344-1352.
7. Watson, C. E., N. Weissbach, L. Kjems, S. Ayalasomayajula, Y. Zhang, I. Chang, M. Navab, S. Hama, G. Hough, S. T. Reddy, et al. 2011. Treatment of patients with cardiovascular disease with L-4F, an apoA-1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52 : 361-373.
8. Navab, M., S. T. Reddy, G. M. Anantharamaiah, S. Imaizumi, G. Hough, S. Hama, and A. M. Fogelman. 2011. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J. Lipid Res. 52 : 1200-1210.
9. Navab, M., S. T. Reddy, G. M. Anantharamaiah, G. Hough, G. M. Buga, J. Danciger, and A. M. Fogelman. 2012. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased infl ammation in lowdensity lipoprotein receptor-null mice. J. Lipid Res. 53 : 437-445.
10. Venkatachalapathi, Y. V., M. C. Philips, R. M. Epand, R. F. Epand, E. M. Tytler, J. P. Segrest, and G. M. Anantharamaiah. 1993. Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins. 15 : 349-359.
11. Yancey, P.G., J. K. Bielicki, W. J. Johnson, S. Lund-Katz, M. N. Palgunachari, G. M. Anantharamaiah, J. P. Segrest, M. C. Philips, and G. H. Rothblat. 1995. Effl ux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry. 34 : 7955-7965.
12. Datta, G., M. Chaddha, S. Hama, M. Navab, A. M. Fogelman, D. W. Garber, V. K. Mishra, R. M. Epand, R. F. Epand, S. Lund-Katz, et al. 2001. Effects of increasing hydrophobicity on the physicalchemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42 : 1096-1104.
13. Anantharamaiah, G. M., V. K. Mishra, D. W. Garber, G. Datta, S. P. Handattu, M. N. Palgunachari, M. Chaddha, M. Navab, S. T. Reddy, and A. M. Fogelman. 2007. Structural requirements for antioxidative and anti-infl ammatory properties of apolipoprotein A-I mimetic peptides. J. Lipid Res. 48 : 1915-1923.
14. Anantharamaiah, G. M. 1986. Synthetic peptide analogs of apolipoproteins. Methods Enzymol. 128 : 627-647.
15. Navab, M., G. M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, N. Yu, B. J. Ansell, G. Datta, D. W. Garber, et al. 2005. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 25 : 1325-1331.
16. Handattu, S. P., D. W. Garber, D. C. Horn, D. W. Hughes, B. Berno, A. D. Bain, V. K. Mishra, M. N. Palgunachri, G. Datta, G. M. Anantharamaiah, et al. 2007. ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J. Biol. Chem. 282 : 1980-1988.
17. Garber, D. W., G. Datta, M. Chaddha, M. N. Palgunachari, S. Y. Hama, A. M. Fogelman, J. P. Segrest, and G. M. Anantharamaiah. 2001. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid Res. 42 : 545-552.
18. Gao, F., S. X. Vasquez, F. Su, S. Roberts, N. Shah, V. Grijalva, S. Imaizumi, A. Chattopadhyay, E. Ganapathy, D. Meriwether, et al. 2011. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr. Biol. (Camb). 3 : 479-489.
19. Navab, M., S. Hama, G. Hough, and A. M. Fogelman. 2003. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation. 108 : 1735-1739.
20. Morgantini, C., S. Imaizumi, V. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2010. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque infl ammation in a murine model of diabetes. Diabetes. 59 : 3223-3228.
21. Frary, A., and E. D. Earle. 1996. An examination of factors affecting the effi ciency of Agrobacterium-mediated transformation of tomato. Plant Cell Rep. 16 : 235-240.
22. Pogrebnyak, N., M. Golovkin, V. Andrianov, S. Spitsin, Y. Smirnov, R. Egolf, and H. Koprowski. 2005. Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine. Proc. Natl. Acad. Sci. USA. 102 : 9062-9067.
23. Hellman, U., C. Wernstedt, J. Gonez, and C. H. Heldin. 1995. Improvement of an "in-gel" digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. Anal. Biochem. 224 : 451-455.
24. Lucini, L., M. Pellizzoni, C. Baffi, and G. P. Molinari. 2012. Rapid determination of lycopene and-carotene in tomato by liquid chro matography/electrospray tandem mass spectrometry. J. Sci. Food Agric. 92 : 1297-1303.
25. Lavecchia, R., and A. Zuorro. 2008. Improved lycopene extraction from tomato peels using cell-wall degrading enzymes. Eur. Food Res. Technol. 228 : 153-158.
26. Su, F., K. R. Kozak, S. Imaizumi, F. Gao, M. W. Amneus, V. Grijalva, C. Ng, A. Wagner, G. Hough, G. Faris-Eisner, et al. 2010. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc. Natl. Acad. Sci. USA. 107 : 19997-20002.
27. Van Lenten, B. J., A. C. Wagner, C. L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamiah, et al. 2008. Anti-infl ammatory apoA-I mimetic peptides bind oxidized lipids with much higher affi nity than human apoA-I. J. Lipid Res. 49 : 2302-2311.
28. Navab, M., G. M. Anantharamaiah, S. Hama, D. W. Garber, M. Chaddha, G. Hough, R. Lallone, and A. M. Fogelman. 2002. Oral administration of an apo A-I mimetic peptide synthesized from D-Amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105 : 290-292.
29. Van Lenten, B. J., A. C. Wagner, M. Navab, G. M. Anantharamiah, S. Hama, S. T. Reddy, and A. M. Fogelman. 2007. Lipoprotein infl ammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J. Lipid Res. 48 : 2344-2353.
30. Navab, M., P. Ruchala, A. J. Waring, R. I. Lehrer, S. Hama, G. Hough, M. N. Palgunachari, G. M. Anantharamiah, and A. M. Fogelman. 2009. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-Amino acids. J. Lipid Res. 50 : 1538-1547.
31. Shen, X., W. Wang, L. Wang, C. Houde, W. Wu, M. Tudor, J. R. Thompson, C. M. Sisk, B. Hubbard, and J. Li. 2012. Identifi cation of genes affecting apolipoprotein B secretion following siRNAmediated gene knockdown in primary human hepatocytes. Atherosclerosis . 222 : 154-157.
32. Zhou, Z., P. Subramanian, G. Sevilmis, B. Globke, O. Soehniein, E. Krshovska, R. Megens, K. Heyll, J. Chun, J. S. Saulnier-Blache, et al. 2011. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from endothelium. Cell Metab. 13 : 592-600.
33. Navab, M., G. M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, A. C. Wagner, J. S. Frank, G. Datta, D. Garber, et al. 2004. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol effl ux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 109 : 3215-3220.
34. Brufau, G., A. K. Groen, and F. Kuipers. 2011. Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion. Arterioscler. Thromb. Vasc. Biol. 31 : 1726-1733.
35. Temel, R. E., and J. M. Brown. 2012. Biliary and nonbiliary contributions to reverse cholesterol transport. Curr. Opin. Lipidol. 23 : 85-90.
36. Danielsen, E. M., G. H. Hansen, K. Rasmussen, L-L. Niels-Christiansen, and F. Frenzel. 2012. Apolipoprotein A-1 (apoA-1) deposition in, and release from, the enterocyte brush border: a possible role in transintestinal cholesterol effl ux (TICE)? Biochim. Biophys. Acta. 1818 : 530-536.